




# ESSENTIAL MESSAGES FROM ESC GUIDELINES

Committee for Practice Guidelines

To improve the quality of clinical practice and patient care in Europe



## HCM

**GUIDELINES FOR THE DIAGNOSIS AND  
MANAGEMENT OF HYPERTROPHIC  
CARDIOMYOPATHY**

For more information

[www.escardio.org/guidelines](http://www.escardio.org/guidelines)



EUROPEAN  
SOCIETY OF  
CARDIOLOGY®

# ESC ESSENTIAL MESSAGES

## 2014 ESC GUIDELINES ON DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY\*

The Task Force for the Diagnosis and Management of Hypertrophic  
Cardiomyopathy of the European Society of Cardiology (ESC)

### Chairperson

#### Perry M. Elliott

Cardiology Department

The Heart Hospital

16-18 Westmoreland Street

London W1G 8PH, UK

Tel: +44 203 456 7898

**Email:** perry.elliott@ucl.ac.uk

### Task Force Members

*Aris Anastasakis (Greece), Michael A. Borger (Germany), Martin Borggrefe (Germany), Franco Cecchi (Italy), Philippe Charron (France), Albert Alain Hagege (France), Antoine Lafont (France), Giuseppe Limongelli (Italy), Heiko Mahrholdt (Germany), William J. McKenna (UK), Jens Mogensen (Denmark), Petros Nihoyannopoulos (UK), Stefano Nistri (Italy), Petronella G. Pieper (Netherlands), Burkert Pieske (Austria), Claudio Rapezzi (Italy), Frans H. Rutten (Netherlands), Christoph Tillmanns (Germany), Hugh Watkins (UK).*

### Additional Contributor

*Constantinos O'Mahony (UK).*

### Other ESC entities having participated in the development of this document:

*Associations: European Association of Cardiovascular Imaging (EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association of the ESC (HFA).*

*Working Groups: Working Group on Cardiovascular Pharmacology and Drug Therapy, Working Group on Cardiovascular Surgery, Working Group on Developmental Anatomy and Pathology, Working Group on Grown-up Congenital Heart Disease, Working Group on Myocardial and Pericardial Diseases.*

*Council: Council for Cardiology Practice, Council on Cardiovascular Primary Care.*

### ESC Staff:

Veronica Dean, Catherine Despres, Nathalie Cameron, Sophia Antipolis, France

\*Adapted from the ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy (Eur Heart J (2014); 35:2733–2779 - doi:10.1093/eurheartj/ ehu283)

# ESSENTIAL MESSAGES FROM FROM THE 2014 ESC GUIDELINES ON DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY

## Table of contents

-  Section 1 - Take home messages
-  Section 2 - Major gaps in evidence

# Take home messages

## 1. Definition

- Hypertrophic cardiomyopathy (HCM) is defined by the presence of increased left ventricular (LV) wall thickness that is not solely explained by abnormal loading conditions.
- In an adult, this represents a wall thickness  $\geq 15$  mm in one or more LV myocardial segments (or  $\geq 13$  mm in a first degree relative of someone with HCM) measured by any imaging technique.

## 2. Prevalence & Aetiology

- Hypertrophic cardiomyopathy (HCM) occurs in 0.02–0.23% of adults, with much lower rates in patients diagnosed under the age of 25 years.
- Hypertrophic cardiomyopathy can be caused by many genetic and non-genetic disorders.
- In up to 60% of patients with HCM, the disease is an autosomal dominant trait caused by mutations in cardiac sarcomere protein genes.
- 5–10% of adult cases are caused by other genetic disorders including inherited metabolic and neuromuscular diseases, chromosome abnormalities and genetic syndromes.

## 3. Genetic Counselling & Testing

- Genetic counselling is recommended in all patients with unequivocal HCM when it cannot be explained solely by a non-genetic cause.
- When a definite causative genetic mutation is identified in a patient, his or her first degree relatives should first be genetically tested. They should undergo clinical evaluation if they are found to carry the same mutation.

## 4. Left ventricular outflow tract obstruction

- Two-thirds of patients with HCM have dynamic obstruction of the left ventricular outflow tract (LVOTO) at rest or during exercise caused by contact between the mitral valve and the interventricular septum during systole.
- In patients with a resting LVOT gradient  $< 50$  mmHg bedside physiological provocation with Valsalva manoeuvre and standing should be routinely performed during echocardiography to determine if LV outflow obstruction can be provoked.
- Exercise stress echocardiography is recommended in symptomatic patients with an LVOT gradient  $< 50$  mmHg at rest or during physiological provocation.
- When a gradient is detected in the LV cavity, the presence of sub-aortic membranes, structural mitral valve leaflet abnormalities and mid-cavity obstruction should be systematically excluded.

## 5. Assessment of symptoms

- Most people with HCM are asymptomatic and have a normal life expectancy but some develop symptoms, often many years after the first manifestation of ECG or echocardiographic abnormalities.
- Systematic 2-D and Doppler echocardiography, exercise testing and ambulatory ECG monitoring are usually sufficient to determine the most likely cause of symptoms.

# Take home messages

## 6. Prevention of Sudden Cardiac Death

- While the risk of sudden death is low for most patients with HCM, a small number are prone to life-threatening ventricular arrhythmias.
- The use of a new risk calculator (HCMRisk-SCD) (<http://doc2do.com/hcm/webHCM.html>) is recommended to guide the use of implantable cardioverter defibrillators (ICD).
- In all patients, clinical efficacy of ICD implantation should be balanced against its potential risk.

## 7. Symptomatic treatment

- In symptomatic patients with LVOTO, the aim is to reduce dyspnoea and chest pain by using drugs, surgical myectomy, alcohol ablation or pacing.
- Therapy in symptomatic patients without LVOTO focuses on management of arrhythmias, reduction of LV filling pressures, and treatment of angina.
- Patients with symptomatic progressive LV systolic or diastolic dysfunction refractory to medical therapy may be candidates for cardiac transplantation.

## 8. Atrial Arrhythmias

- Patients with HCM and paroxysmal, persistent or permanent AF should receive treatment with vitamin K antagonists.
- Lifelong therapy with oral anticoagulants is recommended, even when sinus rhythm is restored.
- Patients in sinus rhythm with LA diameter  $\geq 45$  mm should undergo 6–12 monthly 48-hour ambulatory ECG monitoring to detect AF.

## 9. Management of Pregnancy

- Most women with HCM tolerate pregnancy well but require expert advice and monitoring throughout pregnancy.
- All women with HCM should receive advice on contraception, sterilisation and termination when appropriate.

## 10. Multidisciplinary Care

- Clinicians should consider referral of patients to multidisciplinary teams with expertise in the diagnosis, genetics, risk stratification and management of myocardial disease.

# Major gaps in evidence

1. Genotype-Phenotype Studies.
2. Frequency of screening in mutation carriers and the offspring of affected individuals.
3. Prevention of disease development in asymptomatic mutation carriers without a phenotype.
4. Randomized, controlled, clinical trials of drug therapies for symptom relief.
5. Prevention of left ventricular remodelling and the development of progressive heart failure.
6. Optimal management of asymptomatic left ventricular outflow tract obstruction.
7. Risk stratification and prevention of SCD in the young.



**EUROPEAN  
SOCIETY OF  
CARDIOLOGY®**

EUROPEAN SOCIETY OF CARDIOLOGY  
LES TEMPLIERS  
2035 ROUTE DES COLLES  
CS 80179 BIOT  
06903 SOPHIA ANTIPOLIS CEDEX - FRANCE  
PHONE: +33 (0)4 92 94 76 00  
FAX: +33 (0)4 92 94 76 01  
E-mail: [guidelines@escardio.org](mailto:guidelines@escardio.org)

©2014 The European Society of Cardiology

No part of these Pocket Guidelines may be translated or reproduced in any form without written permission from the ESC.  
The following material was Adapted from the ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy  
(Eur Heart J (2014); 35:2733–2779 - doi:10.1093/eurheartj/ehu283).

To read the full report as published by the European Society of Cardiology, visit our Web Site at:

**[www.escardio.org/guidelines](http://www.escardio.org/guidelines)**

**Copyright © European Society of Cardiology 2014 - All Rights Reserved.**

The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to ESC, Practice Guidelines Department, Les Templiers - 2035 route des colles CS 80179 Biot - 06903 Sophia Antipolis Cedex - France. Email: [guidelines@escardio.org](mailto:guidelines@escardio.org)

**Disclaimer:**

The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.

The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of health care or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and the patient's caregiver where appropriate and/or necessary. Nor do the ESC Guidelines exempt health professionals from taking careful and full consideration of the relevant official updated recommendations or guidelines issued by the competent public health authorities in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

**For more information**

**[www.escardio.org/guidelines](http://www.escardio.org/guidelines)**



**EUROPEAN  
SOCIETY OF  
CARDIOLOGY®**

EUROPEAN SOCIETY OF CARDIOLOGY  
LES TEMPLIERS  
2035 ROUTE DES COLLES  
CS 80179 BIOT  
06903 SOPHIA ANTIPOLIS CEDEX - FRANCE  
PHONE: +33 (0)4 92 94 76 00  
FAX: +33 (0)4 92 94 76 01  
E-mail: [guidelines@escardio.org](mailto:guidelines@escardio.org)

For more information

**[www.escardio.org/guidelines](http://www.escardio.org/guidelines)**